Company / Cost of Revenue
Lilly (Eli) Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$11.1B
FY2025
5-year range
$4.7B / $11.1B
FY2021-FY2025
Trend
+31.3%
vs FY2024
Sector context
#7 of 85
Health Care
What the data says
Among 85 Health Care companies, Lilly (Eli) is in the bottom 8% for cost of revenue. Cost of Revenue has increased for 5 consecutive years, from $4.7B in FY2020 to $11.1B in FY2025.
Based on SEC 10-K filings.
$11.1B in FY2025 with a 5-year CAGR of +18.7%. Top quartile in the Health Care sector.
Increased from $7.3B to $11.1B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +26.3%
- 5-Year CAGR
- +18.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 85This company $11.1B Sector average $2.0B
▼
+457.4% above sector average
Key checks
Key Insights
- Lilly (Eli)'s cost of revenue has grown for 5 consecutive years.
- 5-year CAGR of +18.7%, indicating consistent growth.
- In FY2025, cost of revenue increased 31.3% year-over-year.
- Ranks #7 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.02 (distress zone, below 1.8 threshold)
- Strong profit margin: 31.0%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 77.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.1B | +31.3% |
| FY2024 | $8.4B | +15.1% |
| FY2023 | $7.3B | +33.4% |
| FY2022 | $5.5B | +16.1% |
| FY2021 | $4.7B | +0.8% |
| FY2020 | $4.7B | -0.8% |
| FY2019 | $4.7B | +0.8% |
| FY2018 | $4.7B | -7.1% |
| FY2017 | $5.0B | -11.8% |
| FY2016 | $5.7B | +13.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026